| Pay vs Performance Disclosure - USD ($) | 12 Months Ended |
| Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 |
| Pay vs Performance Disclosure [Table] | | | |
| Pay vs Performance [Table Text Block] | Pay Versus Performance Table Average Value of Initial Fixed $100 Summary Average Investment Based On: Summary Compensation Compensation Peer Group Compensation Compensation Table Total Actually Paid Total Total Net (Loss) / Table Total Actually Paid for Non- to Non-PEO Shareholder Shareholder Income Year for PEO (1) to PEO (1) (2) PEO NEOs (3) NEOs (3) (4) Return (5) Return (6) ($ in millions) (7) 2022 5,628,174 6,654,083 2,352,186 2,665,453 31.64 111.27 (128.3) 2021 5,100,101 1,863,987 2,341,941 1,229,236 28.94 124.89 332.8 2020 4,465,377 (7,341,891) 2,283,388 (599,725) 50.42 125.69 (141.4) (1) Reflects compensation for our CEO, Mr. Kapusta, who served as our Principal Executive Officer (“PEO”) in 2020, 2021 and 2022. (2) The amounts reported for Compensation Actually Paid (“CAP”) have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by our PEO. The following table discloses the adjustments made to the Summary Compensation Table (“SCT”) amounts to calculate the CAP amounts. The valuation assumptions used to calculate fair values did not materially differ from those at the time of the grant. Fiscal year-ended December 31, Reconciliation of Summary Compensation Table Total to Compensation Actually Paid for PEO 2022 ($) 2021 ($) 2020 ($) Summary Compensation Table Total 5,628,174 5,100,101 4,465,377 Deduction for Reported Grant Date Fair Value of Stock Awards (a) (2,464,117) (2,065,081) (1,750,608) Deduction for Reported Grant Date Fair Value of Option Awards (a) (2,006,170) (2,065,074) (1,749,294) Addition of fair value at year-end of equity awards granted during the year that remained outstanding and unvested 5,696,179 2,417,085 2,255,198 Change in fair value at year-end versus prior year-end for awards granted in prior year that remained outstanding and unvested 113,292 (1,571,302) (6,390,497) Change in fair value at vesting date versus prior year-end for awards granted in prior year that vested during the year (313,274) 48,258 (4,172,067) Compensation Actually Paid 6,654,083 1,863,987 (7,341,891) (a) Reflects the total of amounts reported in the Stock Awards and Option Awards columns of the SCT for our PEO in each of the reported years. (3) Reflects the average compensation for the non-PEO NEOs for each respective year presented. The persons included as non-PEO NEOs in each respective year reflects the relevant individuals included in the SCT for each of the years as follows: 2020: Alexander Kuta, Christian Klemt, Ricardo Dolmetsch, Robert Gut and Sander van Deventer; 2021: Alexander Kuta, Christian Klemt and Ricardo Dolmetsch, Pierre Caloz; and, 2022: Alexander Kuta, Christian Klemt, Ricardo Dolmetsch, and Pierre Caloz. (4) The amounts reported for CAP have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by our non-PEO NEOs. The following table discloses the adjustments made to the SCT amounts to calculate the CAP amounts. The valuation assumptions used to calculate fair values did not materially differ from those at the time of the grant. Fiscal year-ended December 31, Reconciliation of Summary Compensation Table Total to Compensation Actually Paid for non-PEO NEOs 2022 ($) 2021 ($) 2020 ($) Summary Compensation Table Total 2,352,186 2,341,941 2,283,388 Deduction for Reported Grant Date Fair Value of Stock Awards (a) (877,719) (826,032) (973,072) Deduction for Reported Grant Date Fair Value of Option Awards (a) (682,913) (897,864) (614,922) Addition of fair value at year-end of equity awards granted during the year that remained outstanding and unvested 1,939,018 1,047,488 1,213,407 Change in fair value at year-end versus prior year-end for awards granted in prior year that remained outstanding and unvested 46,323 (425,980) (1,718,898) Change in fair value at vesting date versus prior year-end for awards granted in prior year that vested during the year (111,442) (10,317) (789,628) Compensation Actually Paid 2,665,453 1,229,236 (599,725) (a) Reflects the total of amounts reported in the Stock Awards and Option Awards columns of the SCT, averaged for our non-PEO NEOs in each of the reported years. (5) Total Shareholder Return (“TSR”) represents the cumulative total shareholder return of investing in our shares for the period beginning on the last trading day of 2019 through the last trading day of each of the years presented in the Pay Versus Performance Table. (6) Peer Group TSR represents the cumulative total shareholder return of the NASDAQ Biotechnology Index (“NBI”) for the period beginning on the last trading day of 2019 through the last trading day of each of the years presented in the Pay Versus Performance Table. The NBI is the peer group used by us for purposes of Item 201(e) of Regulation S-K under the Exchange Act in our Annual Report on Form 10-K for the year ended December 31, 2022. (7) Reflects Net (Loss) / Income as reported in the Company’s Annual Report on Form 10-K for the years ending December 31, 2022, 2021 and 2020. | | |
| Company Selected Measure Name | Total Shareholder Return | | |
| Named Executive Officers, Footnote [Text Block] | (1) Reflects compensation for our CEO, Mr. Kapusta, who served as our Principal Executive Officer (“PEO”) in 2020, 2021 and 2022. (3) Reflects the average compensation for the non-PEO NEOs for each respective year presented. The persons included as non-PEO NEOs in each respective year reflects the relevant individuals included in the SCT for each of the years as follows: 2020: Alexander Kuta, Christian Klemt, Ricardo Dolmetsch, Robert Gut and Sander van Deventer; 2021: Alexander Kuta, Christian Klemt and Ricardo Dolmetsch, Pierre Caloz; and, 2022: Alexander Kuta, Christian Klemt, Ricardo Dolmetsch, and Pierre Caloz. | | |
| Peer Group Issuers, Footnote [Text Block] | (6) Peer Group TSR represents the cumulative total shareholder return of the NASDAQ Biotechnology Index (“NBI”) for the period beginning on the last trading day of 2019 through the last trading day of each of the years presented in the Pay Versus Performance Table. The NBI is the peer group used by us for purposes of Item 201(e) of Regulation S-K under the Exchange Act in our Annual Report on Form 10-K for the year ended December 31, 2022. | | |
| PEO Total Compensation Amount | $ 5,628,174 | $ 5,100,101 | $ 4,465,377 |
| PEO Actually Paid Compensation Amount | $ 6,654,083 | 1,863,987 | (7,341,891) |
| Adjustment To PEO Compensation, Footnote [Text Block] | (2) The amounts reported for Compensation Actually Paid (“CAP”) have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by our PEO. The following table discloses the adjustments made to the Summary Compensation Table (“SCT”) amounts to calculate the CAP amounts. The valuation assumptions used to calculate fair values did not materially differ from those at the time of the grant. Fiscal year-ended December 31, Reconciliation of Summary Compensation Table Total to Compensation Actually Paid for PEO 2022 ($) 2021 ($) 2020 ($) Summary Compensation Table Total 5,628,174 5,100,101 4,465,377 Deduction for Reported Grant Date Fair Value of Stock Awards (a) (2,464,117) (2,065,081) (1,750,608) Deduction for Reported Grant Date Fair Value of Option Awards (a) (2,006,170) (2,065,074) (1,749,294) Addition of fair value at year-end of equity awards granted during the year that remained outstanding and unvested 5,696,179 2,417,085 2,255,198 Change in fair value at year-end versus prior year-end for awards granted in prior year that remained outstanding and unvested 113,292 (1,571,302) (6,390,497) Change in fair value at vesting date versus prior year-end for awards granted in prior year that vested during the year (313,274) 48,258 (4,172,067) Compensation Actually Paid 6,654,083 1,863,987 (7,341,891) (a) Reflects the total of amounts reported in the Stock Awards and Option Awards columns of the SCT for our PEO in each of the reported years. | | |
| Non-PEO NEO Average Total Compensation Amount | $ 2,352,186 | 2,341,941 | 2,283,388 |
| Non-PEO NEO Average Compensation Actually Paid Amount | $ 2,665,453 | 1,229,236 | (599,725) |
| Adjustment to Non-PEO NEO Compensation Footnote [Text Block] | (4) The amounts reported for CAP have been calculated in accordance with Item 402(v) of Regulation S-K and do not reflect compensation actually earned, realized, or received by our non-PEO NEOs. The following table discloses the adjustments made to the SCT amounts to calculate the CAP amounts. The valuation assumptions used to calculate fair values did not materially differ from those at the time of the grant. Fiscal year-ended December 31, Reconciliation of Summary Compensation Table Total to Compensation Actually Paid for non-PEO NEOs 2022 ($) 2021 ($) 2020 ($) Summary Compensation Table Total 2,352,186 2,341,941 2,283,388 Deduction for Reported Grant Date Fair Value of Stock Awards (a) (877,719) (826,032) (973,072) Deduction for Reported Grant Date Fair Value of Option Awards (a) (682,913) (897,864) (614,922) Addition of fair value at year-end of equity awards granted during the year that remained outstanding and unvested 1,939,018 1,047,488 1,213,407 Change in fair value at year-end versus prior year-end for awards granted in prior year that remained outstanding and unvested 46,323 (425,980) (1,718,898) Change in fair value at vesting date versus prior year-end for awards granted in prior year that vested during the year (111,442) (10,317) (789,628) Compensation Actually Paid 2,665,453 1,229,236 (599,725) (a) Reflects the total of amounts reported in the Stock Awards and Option Awards columns of the SCT, averaged for our non-PEO NEOs in each of the reported years. | | |
| Compensation Actually Paid vs. Total Shareholder Return [Text Block] | | | |
| Compensation Actually Paid vs. Net Income [Text Block] | | | |
| Tabular List [Table Text Block] | Tabular List of Company Performance Measures As described in our CD&A, we believe that compensation should pay for performance, align interest with our shareholders, use at risk compensation to incentivize executives, and attract and retain talented executives. We seek to align compensation opportunities for our NEOs with strategic priorities for the company, which largely reflect non-financial measures. Total Shareholder Return is the only financial measure currently used in our executive compensation program to assess performance in respect of a portion of the 2021 PSU awards on a relative basis. As a result of Total Shareholder Return already being included in the pay versus performance table, no company-selected measure is reported. Abular List of Tabular List of Most Important Performance Measures Total Shareholder Return | | |
| Total Shareholder Return Amount | $ 31.64 | 28.94 | 50.42 |
| Peer Group Total Shareholder Return Amount | 111.27 | 124.89 | 125.69 |
| Net Income (Loss) | $ (128,300,000) | 332,800,000 | (141,400,000) |
| PEO Name | Mr. Kapusta | | |
| Measure [Axis]: 1 | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Measure Name | Total Shareholder Return | | |
| Non-GAAP Measure Description [Text Block] | Total Shareholder Return is the only financial performance measure (per the definition in Item 402(v)(2) of Regulation S-K) currently used by uniQure, which already features in the Pay versus Performance Table. Accordingly, no company-selected measure is identified or reported. | | |
| PEO [Member] | Deduction for Reported Grant Date Fair Value of Stock Awards (a) | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | $ (2,464,117) | (2,065,081) | (1,750,608) |
| PEO [Member] | Deduction for Reported Grant Date Fair Value of Option Awards (a) | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | (2,006,170) | (2,065,074) | (1,749,294) |
| PEO [Member] | Addition of fair value at year-end of equity awards granted during the year that remained outstanding and unvested | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 5,696,179 | 2,417,085 | 2,255,198 |
| PEO [Member] | Change in fair value at year-end versus prior year-end for awards granted in prior year that remained outstanding and unvested | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 113,292 | (1,571,302) | (6,390,497) |
| PEO [Member] | Change in fair value at vesting date versus prior year-end for awards granted in prior year that vested during the year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | (313,274) | 48,258 | (4,172,067) |
| Non-PEO NEO [Member] | Deduction for Reported Grant Date Fair Value of Stock Awards (a) | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | (877,719) | (826,032) | (973,072) |
| Non-PEO NEO [Member] | Deduction for Reported Grant Date Fair Value of Option Awards (a) | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | (682,913) | (897,864) | (614,922) |
| Non-PEO NEO [Member] | Addition of fair value at year-end of equity awards granted during the year that remained outstanding and unvested | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 1,939,018 | 1,047,488 | 1,213,407 |
| Non-PEO NEO [Member] | Change in fair value at year-end versus prior year-end for awards granted in prior year that remained outstanding and unvested | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | 46,323 | (425,980) | (1,718,898) |
| Non-PEO NEO [Member] | Change in fair value at vesting date versus prior year-end for awards granted in prior year that vested during the year | | | |
| Pay vs Performance Disclosure [Table] | | | |
| Adjustment to Compensation Amount | $ (111,442) | $ (10,317) | $ (789,628) |
